Drug class profile · refreshed daily from federal data

Alkaloid

3 molecules in this class, $124.2M combined CY2024 Part D spend across 2.3M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Alkaloid class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $124.2Mcombined across class
Total Rx claims: 2.3M1.1M unique beneficiaries
Generic mfrs (active): 17across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Colchicine

Brand: Colcrys · 2.3M Part D claims (CY24) · 1.1M beneficiaries · First FDA approval: 2009-09-01

14 generic mfrs 1 plans require PA

Low NADAC$0.129

→

Avg plan cost$1.03

Part D spend $124.2M 8× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Colchicine Tablets

Brand: LODOCO · — Part D claims (CY24) · First FDA approval: 2023-06-16

Brand-only (no generics) 14 plans require PA

Low NADAC$17.00

→

Avg plan cost$17.00

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Probenecid and Colchicine

— Part D claims (CY24) · First FDA approval: 1982-10-01

3 generic mfrs 0 plans require PA

Low NADAC$0.777

→

Avg plan cost$0.777

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.